Who Paid My Doc Search
Menu
Organisation paid for research Program year 2021 Source: CMS Open Payments

Pra Health Sciences

Neither a doctor nor a teaching hospital

Research payments

$2,548,495

70 payments

Through program year 2021, Pra Health Sciences is reported as receiving $2,548,495 in research payments, across 70 payments.

By program year

3 rows
Year Kind Amount Payments
2021 Research $348,877 2
2020 Research $1,093,427 62
2019 Research $1,106,191 6

Breakdown

Who paid Research payments · program years 2019–2021
  1. Hexal AG $1,103,094 5 payments
  2. Novartis Pharmaceuticals Corporation $788,596 3 payments
  3. Merck Sharp & Dohme Corporation $268,808 3 payments
  4. Swedish Orphan Biovitrum AB $212,752 50 payments
  5. Biodelivery Sciences International, Inc. $175,245 9 payments
Studies the money was for Research payments · program years 2019–2021
  1. La-Ep06-104 $1,103,094 5 payments
  2. A Randomized, Open-Label, Single-Dose, Parallel-Group Study in Healthy Subjects to Assess the PK Comparability of Canakinumab With Either One Injection (200 MG) of Pre-Filled Syringe in Needle Safety Device Or Auto-Injector Compared to Two Injections (150 $655,044 1 payment
  3. A Clinical Trial to Study the Effect of a Single Dose of Islatravir MK-8591 on the Pharmacokinetics of Methadone $265,407 1 payment
  4. Sobi.Anakin-401 $212,752 50 payments
  5. Single Dose Crossover Study to Compare the Respiratory Drive After Administration of Belbuca, Oxycodone and Placebo. $175,245 9 payments
  6. A Phase I, Open-Label, Single-Dose, Randomized, Cross-Over, 3 Parts Study to Evaluate in Healthy Subjects the Relative Bioavailability of Eltrombopag New Capsule Formulation (CPS) in Comparison to the Reference Marketed Film-Coated Tablets (FCT) (Part1), the Pharmacokinetic Comparability of Eltrombopag CPS and Marketed FCT (Part 2) and the Effect of Food on the Pharmacokinetics of Eltrombopag Administered As CPS (Part 3) $83,470 1 payment
  7. A Phase I, Open-Label, Single-Dose, Randomized, Cross-Over, 3 Parts Study to Evaluate in Healthy Subjects the Relative Bioavailability of Eltrombopag New Capsule Formulation (CPS) in Comparison to the Reference Marketed Film-Coated Tablets (FCT) (Part1), $50,082 1 payment
  8. A Randomized, Double-Blinded Clinical Trial to Assess the Safety, Tolerability and Pharmacokinetics of MK-4334 in Participants With Alzheimer s Clinical Syndrome on a Stable Dose of Donepezil $3,098 1 payment
  9. A Clinical Trial to Study the Effect of a Single Dose of Islatravir MK-8591 on the Pharmacokinetics of Methadone $304 1 payment
What the money was spent on Research payments · program years 2019–2021
  1. Other $175,245 9 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2021

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record